XTalks
JULY 29, 2024
Participant recruitment is challenging, especially in those indications in which there are competing clinical trials necessitating a comprehensive understanding of the disease research ‘landscape’ and targeted outreach and stakeholder collaboration. Sharing patient experiences is also important for gathering real-world insights.
FDA Law Blog
MARCH 13, 2023
Who better than people living with a condition to inform drug companies, physicians, academics, and the FDA on what it is like to live with their condition, what symptoms most impact their lives, what goes into their decision about whether to participate in a clinical trial, and what kind of treatment effects would be most meaningful to them?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
DECEMBER 1, 2020
As the research and medical community learns more about population variances in disease outcomes, whether as a result of regional genetic profiles, socioeconomic factors, or environmental inputs, it’s become necessary to ensure that clinical research trials include broad swaths of global participants. billion in 2019.
pharmaphorum
NOVEMBER 16, 2022
Having presented the data from the 24-month phase 3 trial at the American Academy of Ophthalmology (AAO) annual meeting, Dr Wykoff set aside some time to go into further detail with pharmaphorum about how the results were received, and what glimmer of hope this might hold for patients with GA.
XTalks
MARCH 7, 2024
Experts discuss the therapeutic landscape, treatment gaps, regulatory considerations and clinical trial strategies. The webinar provides insights into a novel method that facilitates detailed genetic analysis of breast cancer, marrying the depth of whole-genome studies with the precision of targeted analysis at the single-cell level.
The Pharma Data
SEPTEMBER 3, 2020
Our findings could help to pick out those patients most likely to benefit from immunotherapy – and we’re keen to translate our work into clinical trials to test the benefit of different immunotherapeutic strategies to tackle this hard-to-treat form of pancreatic cancer.”. Source link.
The Pharma Data
DECEMBER 11, 2020
Bhavana Bhatnagar, an Ohio State University (OSU) cancer specialist and lead author of the second study, “Access can potentially be an issue, in terms of being able to get to tertiary care centers that have clinical trial availability and physicians who have disease-specific expertise in treating some of these rarer cancers.
Expert insights. Personalized for you.
105 
Let's personalize your content